Impact of arterial occlusion location on early neurological deterioration in patients with minor stroke treated with intravenous thrombolysis. The MINORCAT-END study
Por:
Font, MA, García-Sánchez, SM, Mengual, JJ, Avellaneda-Gomez, C, Boned, S, Aragonès, JM, Silva, Y, Martínez, M, Doncel-Moriano, A, Ustrell, X, Camps-Renom, P, Mauri-Capdevila, G, Purroy, F, Rodríguez-Campello, A, Palomeras, E, Krupinski, J, Figueras-Aguirre, G, Catena, E, García-Alhama, J, Esteve-Belloch, P, Matos, N, Colom, C, Aguilo, O, Coll, A, Díaz, G, Tio, E, Ortega, O, Alfonso, S, Jiménez-Fàbrega, X, Salvat-Plana, M, Elosua, R, de la Ossa, NP, Abilleira, S and Gomez-Choco, M
Publicada:
17 dic 2025
Ahead of Print:
17 dic 2025
Resumen:
Purpose To assess the proportion of early neurological deterioration (END) in patients with minor stroke, its impact on 3-month clinical outcomes, and the influence of large vessel occlusion (LVO) location on END development. Methods We analyzed patients from the CICAT Code Stroke Registry in Catalonia, Spain, between January 1, 2016, and December 31, 2021. Inclusion criteria were baseline NIHSS <= 5, treatment with intravenous thrombolysis (IVT) with or without endovascular treatment (EVT), and available acute vascular imaging. END was defined as an NIHSS increase of >= 4 points at 24-36 h post-treatment. Poor clinical outcome was defined as modified Rankin Scale (mRS) 3-6 at 3 months. Findings A total of 1,380 patients were included (median age 71 [IQR 59-79] years; 59% male; median NIHSS 4 [IQR 3-5]). LVO was present in 282 patients (20.4%). END occurred in 73 patients (5.3%): 12.1% with LVO vs. 3.6% without LVO (p < 0.001). LVO was the strongest predictor of END (OR 3.73; 95% CI 2.30-6.06; p < 0.001), regardless of occlusion level. Poor 3-month outcome was observed in 74% of patients with END, compared to 26.8% without END (p < 0.001). END independently predicted poor outcome (OR 6.79; 95% CI 3.23-14.31). Conclusions In minor stroke patients treated with IVT or IVT + EVT, LVO was the primary driver of END even for mediun-sized arteries. END emerged as the strongest predictor of poor 3-month functional outcome.
Filiaciones:
Font, MA:
Consorci Hosp Vic, Neurol Dept, Vic, Spain
UCC, Escola Doctorat, UVIC, Vic, Spain
García-Sánchez, SM:
Complex Hosp Univ Moises Broggi, Neurol Dept, St Joan Despi, Spain
Mengual, JJ:
Complex Hosp Univ Moises Broggi, Neurol Dept, St Joan Despi, Spain
Avellaneda-Gomez, C:
Complex Hosp Univ Moises Broggi, Neurol Dept, St Joan Despi, Spain
Boned, S:
Complex Hosp Univ Moises Broggi, Neurol Dept, St Joan Despi, Spain
Aragonès, JM:
Consorci Hosp Vic, Neurol Dept, Vic, Spain
Silva, Y:
Hosp Univ Dr Josep Trueta, Neurol Dept, Girona, Spain
Martínez, M:
Hosp Univ Germans Trias i Pujol, Neurol Dept, Cerebrovasc Disorders Unit, Badalona, Spain
Doncel-Moriano, A:
Hosp Clin Barcelona, Neurol Dept, Funct Unit Cerebrovasc Disorders, Barcelona, Spain
Ustrell, X:
Hosp Univ Joan XXIII, Neurol Dept, Tarragona, Spain
Camps-Renom, P:
Hosp Santa Creu & Sant Pau, Neurol Dept, Barcelona, Spain
Mauri-Capdevila, G:
Hosp Univi Arnau de Vilanova, Neurol Dept, UdL, Grp Neurociencies Clin IRBLleida, Lleida, Spain
Purroy, F:
Hosp Univi Arnau de Vilanova, Neurol Dept, UdL, Grp Neurociencies Clin IRBLleida, Lleida, Spain
Rodríguez-Campello, A:
Hosp del Mar, Neurol Dept, Barcelona, Spain
Palomeras, E:
Hosp Mataro, Neurol Dept, Mataro, Spain
Krupinski, J:
F Ass Mutua Terrassa, Neurol Dept, Terrassa, Spain
Manchester Met Univ, Dept Life Sci, Manchester, England
Figueras-Aguirre, G:
Hosp Parc Tauli, Neurol Dept, Sabadell, Spain
Catena, E:
Consorci Sanit Alt Penedes Garraf, Neurol Dept, Vilafranca Del Penedes, Spain
García-Alhama, J:
Consorci Sanit Alt Penedes Garraf, Neurol Dept, Vilafranca Del Penedes, Spain
Esteve-Belloch, P:
Hosp Verge de la Cinta, Neurol Dept, Tortosa, Spain
Matos, N:
Hosp St Joan de Deu, Neurol Dept, Fundacio Althaia, Manresa, Spain
Colom, C:
Hosp Igualada, Emergency Dept, Igualada, Spain
Aguilo, O:
Univ Cent Catalunya, Univ Vic, Fac Med, Vic, Spain
Hosp Olot & Comarcal de la Garrotxa, Emergency Dept, Girona, Spain
Inst Recerca & Innovac Ciencies Vida Salut Catalu, Tissue Repair & Regenerat Lab TR2Lab, Vic, Spain
Coll, A:
Hosp Olot & Comarcal de la Garrotxa, Emergency Dept, Girona, Spain
Díaz, G:
Hosp Campdevanol, Emergency Dept, Campdevanol, Spain
Tio, E:
Consorci Hosp Vic, Neurol Dept, Vic, Spain
Univ Cent Catalunya, Univ Vic, Fac Med, Vic, Spain
Ortega, O:
Consorci Hosp Vic, Neurol Dept, Vic, Spain
Alfonso, S:
Consorci Hosp Vic, Neurol Dept, Vic, Spain
Jiménez-Fàbrega, X:
Generalitat Catalunya, Invest & Dev Area, Serv Emergencies Med, Barcelona, Spain
Salvat-Plana, M:
Pla Malaltia Vasc Cerebral, Dept Salut, Barcelona, Spain
Elosua, R:
Univ Cent Catalunya, Univ Vic, Fac Med, Vic, Spain
Hosp del Mar, Res Inst IMIM, Barcelona, Spain
Inst Salud Carlos III, CIBER Enfermedades Cardiovasc, Barcelona, Spain
Abilleira, S:
Pla Malaltia Vasc Cerebral, Dept Salut, Barcelona, Spain
Gomez-Choco, M:
Complex Hosp Univ Moises Broggi, Neurol Dept, St Joan Despi, Spain
Complex Hosp Univ Moises Broggi, Neurol Dept, Oriol Martorell 12, St Joan Despi 08970, Spain
|